Mercado mundial de trastornos de la vejiga: tendencias de la industria y pronóstico hasta 2029

Solicitud de índiceSolicitud de índice Hable con el analistaHable con el analista Comprar ahoraComprar ahora Consultar antes de comprarConsultar antes Informe de muestra gratuitoInforme de muestra gratuito

Mercado mundial de trastornos de la vejiga: tendencias de la industria y pronóstico hasta 2029

  • Pharmaceutical
  • Published Report
  • Sep 2022
  • Global
  • 350 Páginas
  • Número de tablas: 247
  • Número de figuras: 65

>Mercado mundial de trastornos de la vejiga, por tipo (cistitis, incontinencia urinaria, vejiga hiperactiva, cistitis intersticial, cáncer de vejiga), tipo de tratamiento (cirugía, medicación, no quirúrgico), usuario final (hospitales, clínicas, centros de cirugía ambulatoria , otros), canal de distribución (directo, minorista) - Tendencias de la industria y pronóstico hasta 2029.

Mercado de trastornos de la vejiga

Análisis y perspectivas del mercado de trastornos de la vejiga 

Los trastornos de la vejiga son un grupo de trastornos que pueden afectar la actividad diaria de la vida humana. Algunos de los trastornos de la vejiga más comunes son la cistitis, en la que la vejiga se infecta y causa inflamación; la incontinencia urinaria (pérdida del control de la vejiga); la cistitis intersticial (dolor de vejiga y micción frecuente y urgente); y la vejiga hiperactiva (una afección en la que la vejiga comprime la orina). Los trastornos de la vejiga pueden afectar la calidad de vida y causar otros problemas de salud. Los cambios y problemas de salud, incluidos los factores del sistema nervioso y del estilo de vida, pueden causar o contribuir a la IU en hombres y mujeres.

Mercado de trastornos de la vejiga

Mercado de trastornos de la vejiga

Los trastornos de vejiga más comunes son la vejiga hiperactiva y la incontinencia urinaria. Estos problemas están asociados con el sistema nervioso. Los nervios transmiten mensajes desde el cerebro hasta la vejiga, indicando que los músculos se contraen o se relajan.

Se espera que el mercado mundial de trastornos de la vejiga crezca en el período de pronóstico de 2022 a 2029. Data Bridge Market Research analiza que el mercado está creciendo con una CAGR del 11,4% en el período de pronóstico de 2022 a 2029 y se espera que alcance los USD 22.342,48 millones para 2029.

Métrica del informe

Detalles

Período de pronóstico

2022 a 2029

Año base

2021

Años históricos

2020 (Personalizable 2019-2014)

Unidades cuantitativas

Ingresos en millones de USD

Segmentos cubiertos

Por tipo (cistitis, incontinencia urinaria, vejiga hiperactiva, cistitis intersticial, cáncer de vejiga), tipo de tratamiento (cirugía, medicación, no quirúrgico), usuario final (hospitales, clínicas, centros de cirugía ambulatoria, otros), canal de distribución (directo, minorista)

Países cubiertos

EE. UU., Canadá, México, Alemania, Reino Unido, Francia, Italia, España, Turquía, Rusia, Países Bajos, Suiza, Bélgica y resto de Europa, China, Japón, India, Corea del Sur, Australia, Singapur, Tailandia, Malasia, Indonesia, Filipinas, Vietnam, resto de Asia-Pacífico, Brasil, Argentina, Perú, resto de Sudamérica, Sudáfrica, Arabia Saudita, Emiratos Árabes Unidos, Egipto, Israel, resto de Oriente Medio y África

Actores del mercado cubiertos

Las principales empresas que operan en el mercado son Medtronic, Laborie, Boston Scientific Corporation, Pfizer Inc., Astellas Pharma Inc., KYORIN Pharmaceutical Co., Ltd. (una subsidiaria de KYORIN Holdings, Inc.), Bristol-Myers Squibb Company, Johnson & Johnson Services, Inc., Axonics, Inc., Merck & Co., Inc., Viatris Inc., Blue Wind Medical, Valencia Technologies, Gaylord Chemical Company, LLC, Coloplast Corp, AbbVie Inc., Sun Pharmaceutical Industries Ltd., Zydus Group, Swati Spentose, Urovant Sciences, entre otras.

Definición del mercado de trastornos de la vejiga a nivel mundial

Los trastornos relacionados con la vejiga incluyen cistitis (inflamación de la vejiga, a menudo causada por una infección), incontinencia urinaria (pérdida del control de la vejiga), vejiga hiperactiva (una afección en la que la vejiga expulsa la orina en el momento equivocado), cistitis intersticial (un problema crónico que causa dolor de vejiga y micción frecuente y urgente) y cáncer de vejiga.

Los médicos realizan diferentes pruebas para diagnosticar el trastorno de la vejiga, que incluyen radiografías, análisis de orina y un examen de la pared de la vejiga con un instrumento llamado cistoscopio. El tratamiento del trastorno depende de la causa del problema e incluye medicamentos, cirugías (en casos graves) y procedimientos no quirúrgicos.

Los medicamentos anticolinérgicos son la primera línea de farmacoterapia en el síndrome de vejiga hiperactiva (VHA). La VHA es un síntoma clínico que se caracteriza por la urgencia de orinar, que es difícil de posponer; por lo general, se considera que la frecuencia de orinar más de ocho veces al día forma parte de la VHA. Los medicamentos anticolinérgicos inhiben los receptores muscarínicos en el músculo detrusor que reducen la contractilidad de la vejiga. Para reducir los efectos secundarios, se están desarrollando nuevos medicamentos con una selectividad vesical mejorada y formulaciones de liberación prolongada. La mayoría de los medicamentos más recientes son igualmente eficaces para reducir los síntomas de la vejiga hiperactiva.

Dinámica del mercado mundial de trastornos de la vejiga

Conductores

  • INICIATIVAS ESTRATÉGICAS ADOPTADAS POR LOS AGENTES DEL MERCADO

Los trastornos de la vejiga son una serie de problemas de la vejiga que pueden afectar las actividades físicas diarias. Los trastornos de la vejiga más comunes son la cistitis, la cistitis intersticial, la vejiga hiperactiva, la incontinencia urinaria y el cáncer de vejiga. La mayoría de los problemas de vejiga son causados ​​por una infección bacteriana que ingresa en el tracto urinario.

Varias iniciativas estratégicas de los actores del mercado en términos de colaboración, adquisición, asociación y otros, les permiten aumentar la cartera de productos de su empresa, lo que lleva a la expansión del mercado y, por lo tanto, mejora la demanda de productos entre los clientes, lo que en última instancia proporciona a los actores del mercado la posibilidad de obtener los máximos ingresos.

  • CRECIMIENTO DE LA POBLACIÓN GERIÁTRICA

El envejecimiento es un factor de riesgo importante que puede asociarse con trastornos relacionados con la vejiga. El envejecimiento provoca cambios neurológicos, anatómicos y bioquímicos en la función de la vejiga, lo que puede provocar el desarrollo de VAH. La vejiga hiperactiva es el problema más común entre la población geriátrica. La población que envejece sufre diversos problemas y trastornos asociados con la vejiga, por lo que son los usuarios predominantes de servicios y soluciones de gestión de la salud crónica.

According to the noble study, the prevalence rate of overactive bladder is approximately 16.9 in women and men, around 16.0%, and the prevalence of OAB is growing with age. However, treatment guidelines specify the preferred first-, second-, and third-line OAB therapy strategies. Bladder disorders are associated with Neurologic disorders such as dementia, and in this age group, OAB is very challenging for the senior population. Over the last few decades, the old age population has been drastically growing worldwide.

  • RISING R&D INVESTMENTS AND LAUNCH OF NOVEL THERAPIES IN UPCOMING YEARS

Various treatment options and innovative therapies are available for OAB and other bladder disorders. Many biopharmaceutical and pharmaceutical companies are investing in various unconventional therapies for bladder disorders, which are expected to launch during the forecast period.

  • COMBINATION OF DIFFERENT TARGET THERAPIES

Combination Therapies are much more effective than monotherapy, without additional side effects. Combination Therapies are a safe and effective alternative for individuals with refractory bladder conditions. Combining different target therapy strategies is the best approach to relieve patients of bladder disorders. Oral medication and behavioral therapy should be considered for the patients' refractory treatment. Various advanced target therapies are available such as sacral neuromodulation, intradetrusor injection of a botulinum toxin A and percutaneous tibial nerve stimulation. These are advanced treatments and more effective as compared to oral agents.

Mercado de trastornos de la vejiga

Opportunities

  • SURGE IN NOVEL TECHNOLOGICAL ADVANCEMENTS

Chronic diseases are considered one of the major leading causes of death in developing countries worldwide. Therefore, the importance of healthcare management of chronic management is increased among public health practitioners.

Bladder disorder management now places a strong emphasis on assisting patients with a range of alternatives for self-care and a range of consultation services to educate patients about their illness state and move forward. These therapies also assist patients in getting over emotional trauma and anxiety, which may act as a counter-protective mechanism.

Rising technical breakthroughs allow healthcare organizations to explore innovative services and solutions for managing chronic bladder disorders. Since they are not required to stay in the hospital for an extended period of time, they have also decreased costs and patient volume. Furthermore, lowering hospital visits and stays makes this development convenient for older adults. Considering the favorable aspects, many organizations and businesses are developing and implementing the most recent technologies in managing chronic diseases to enhance patient outcomes.

  • RISING DISEASE MANAGEMENT PROGRAMS

People with bladder-related problems typically need more medical services, such as hospital stays, doctor visits, and prescription medications. The rise in the number of people living longer with many chronic problems and increasing healthcare expenditures has encouraged better healthcare plans.

Disease management is one strategy that tries to improve care while lowering the expense of caring for the chronically ill. Programs for managing diseases aim to enhance the health of people with certain chronic disorders such as bladder disorders while lowering the demand for medical services and associated expenses for consequences that can be avoided, such as hospital stays and emergency visits. These programs also include information regarding chronic disease management services and solutions. These are becoming very popular owing to the rising prevalence of chronic diseases worldwide. Government and healthcare organizations have organized and implemented these chronic diseases with multiple disease management programs such as bladder cancer, interstitial cystitis, and overactive bladder management programs. Since disease management programs can significantly improve self-care practices and reduce hospital visits and staying periods to a more excellent extent, they receive more attention among people.

Restraints/Challenges

However, the difficulty in diagnosing the disease and the cost of the treatments and diagnostics are high due to the procedure of various checkpoints along with the high-tech technologies and modalities to perform the procedures. The cost of the procedure generally gets elevated because of the high cost of the advanced technological devices used in the treatment, which is expected to restrain the market growth.

This bladder disorders market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Global bladder disorders market, contact Data Bridge Market Research for an Analyst Brief. Our team will help you make an informed market decision to achieve market growth.

Post COVID-19 Impact on Global Bladder Disorders Market

COVID-19 has positively affected the market. Lockdowns and isolation during pandemics complicate disease management and medication adherence. Hence the use of various treatment drugs has widely increased in the world's population. Hence, the pandemic has effected positively on this market

Recent Development

  • In June 2022, Valencia Technologies Corporation announced the implantable neuromodulation technology product eCoin®, which is reshaping the delivery of long-term therapy for bladder control, is a tibial implant for Urge Urinary Incontinence (UUI). eCoin® received premarket approval (PMA) from the U.S. Food and Drug Administration (FDA) in March 2022, making it the first and only FDA-approved implantable tibial neurostimulator indicated for the treatment of urge urinary incontinence (UUI). This new product has helped the company to increase its portfolio

Global Bladder Disorders Market Scope

Global bladder disorders market is segmented into treatment, end user, and distribution channel types. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.

Type

  • Cystitis
  • Urinary Incontinence
  • Overactive Bladder
  • Interstitial Cystitis
  • Bladder Cancer

On the basis of type, the global bladder disorders market is segmented into cystitis, urinary incontinence, overactive bladder, interstitial cystitis, bladder cancer.

Treatment type

  • Surgery
  • Medications
  • Others

On the basis of product, the global bladder disorders market is segmented into surgery, medication, and others.

End User

  • Hospital
  • Clinics
  • Ambulatory Surgery centers
  • Others

On the basis of end users, the global bladder disorders market is segmented into hospitals, clinics, ambulatory surgery centers, and others.

Distribution Channel

  • Direct
  • Retail

Mercado de trastornos de la vejiga

On the basis of distribution channel, the global bladder disorders market is segmented into direct and retail.

Global Bladder Disorders Market Regional Analysis/Insights   

The global bladder disorders market is analyzed, and market size insights and trends are provided by country, type, treatment type, end user, and distribution channel, as referenced above.

Countries covered in this market are U.S., Canada, Mexico, Germany, U.K., France, Italy, Spain, Turkey, Russia, Netherlands, Switzerland, Belgium and Rest of Europe, China, Japan, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Brazil, Argentina, Peru, Rest of South America, South Africa, Saudi Arabia, U.A.E, Egypt, Israel, Rest of the Middle East and Africa.

North America dominates the global bladder disorders market in terms of market share and revenue and will continue to flourish its dominance during the forecast period. This is due to the high prevalence of overactive bladder disorder in the region, and growing R&D investments and the launch of novel therapies are boosting the market

Mercado de trastornos de la vejiga

La sección de países del informe también proporciona factores de impacto de mercado individuales y cambios en las regulaciones del mercado que afectan las tendencias actuales y futuras del mercado. Los puntos de datos, como las ventas de productos nuevos y de reemplazo, la demografía del país, la epidemiología de las enfermedades y los aranceles de importación y exportación, son algunos de los principales indicadores utilizados para pronosticar el escenario del mercado para países individuales. Además, se consideran la presencia y disponibilidad de marcas globales y los desafíos que enfrentan debido a la alta competencia de las marcas locales y nacionales y el impacto de los canales de venta al proporcionar un análisis de pronóstico de los datos del país.

Análisis del panorama competitivo y de la cuota de mercado global de los trastornos de la vejiga

El panorama competitivo del mercado global de trastornos de la vejiga proporciona detalles sobre los competidores. Los detalles incluyen una descripción general de la empresa, las finanzas de la empresa, los ingresos generados, el potencial de mercado, la inversión en investigación y desarrollo, las nuevas iniciativas de mercado, la presencia global, los sitios e instalaciones de producción, las capacidades de producción, las fortalezas y debilidades de la empresa, el lanzamiento de productos, la amplitud y la variedad de productos y el dominio de las aplicaciones. Los puntos de datos anteriores solo están relacionados con el enfoque de la empresa en el mercado global de trastornos de la vejiga.

Algunos de los principales actores que operan en el mercado global de trastornos de la vejiga son Medtronic, Laborie, Boston Scientific Corporation, Pfizer Inc., Astellas Pharma Inc., KYORIN Pharmaceutical Co., Ltd. (una subsidiaria de KYORIN Holdings, Inc.), Bristol-Myers Squibb Company, Johnson & Johnson Services, Inc., Axonics, Inc., Merck & Co., Inc., Viatris Inc., Blue Wind Medical, Valencia Technologies, Gaylord Chemical Company, LLC, Coloplast Corp, AbbVie Inc., Sun Pharmaceutical Industries Ltd., Zydus Group, Swati Spentose, Urovant Sciences, entre otros.

Metodología de la investigación

La recopilación de datos y el análisis del año base se realizan utilizando módulos de recopilación de datos con muestras de gran tamaño. Los datos del mercado se analizan y estiman utilizando modelos estadísticos y coherentes del mercado. Además, el análisis de la participación de mercado y el análisis de tendencias clave son los principales factores de éxito en el informe de mercado. La metodología de investigación clave utilizada por el equipo de investigación de DBMR es la triangulación de datos, que implica la extracción de datos, el análisis del impacto de las variables de datos en el mercado y la validación primaria (experto en la industria). Los modelos de datos incluyen la cuadrícula de posicionamiento de proveedores, el análisis de la línea de tiempo del mercado, la descripción general y la guía del mercado, la cuadrícula de posicionamiento de la empresa, el análisis de la participación de mercado de la empresa, los estándares de medición, el análisis global frente a regional y el análisis de la participación de los proveedores. Solicite una llamada de un analista en caso de tener más consultas.


SKU-

Obtenga acceso en línea al informe sobre la primera nube de inteligencia de mercado del mundo

  • Panel de análisis de datos interactivo
  • Panel de análisis de empresas para oportunidades con alto potencial de crecimiento
  • Acceso de analista de investigación para personalización y consultas
  • Análisis de la competencia con panel interactivo
  • Últimas noticias, actualizaciones y análisis de tendencias
  • Aproveche el poder del análisis de referencia para un seguimiento integral de la competencia
Solicitud de demostración

Tabla de contenido

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF GLOBAL BLADDER DISORDERS MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 TYPE LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 MARKET END USER COVERAGE GRID

2.11 VENDOR SHARE ANALYSIS

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTEL ANALYSIS

4.2 PORTER'S FIVE FORCES

4.3 GLOBAL BLADDER DISORDERS MARKET, PIPELINE ANALYSIS

5 GLOBAL BLADDER DISORDER MARKET: REGULATIONS

5.1 THE U.S. REGULATORY FRAMEWORK FOR BLADDER DISOREDER MEDICATION

5.2 EUROPE REGULATORY FRAMEWORK FOR BLADDER DISORDER DRUGS

5.3 JAPAN REGULATORY GUIDANCE ON BLADDER DISORDER DRUGS

6 GLOBAL BLADDER DISORDERS MARKET OVERVIEW

6.1 DRIVERS

6.1.1 STRATEGIC INITIATIVES ADOPTED BY MARKET PLAYERS

6.1.2 GROWING GERIATRIC POPULATION

6.1.3 RISING R&D INVESTMENTS AND LAUNCH OF NOVEL THERAPIES IN UPCOMING YEARS

6.1.4 COMBINATION OF DIFFERENT TARGET THERAPIES

6.2 RESTRAINTS

6.2.1 HIGH COST ASSOCIATED WITH BLADDER DISORDER DIAGNOSTIC TREATMENT

6.2.2 PRODUCTS RECALLS FROM MARKET

6.3 OPPORTUNITIES

6.3.1 SURGE IN NOVEL TECHNOLOGICAL ADVANCEMENTS

6.3.2 RISING DISEASE MANAGEMENT PROGRAMS

6.4 CHALLENGES

6.4.1 LACK OF AWARENESS ABOUT BLADDER DISORDERS RELATED PROBLEMS

6.4.2 PATENT EXPIRY OF DRUGS

7 GLOBAL BLADDER DISORDERS MARKET, BY TYPE

7.1 OVERVIEW

7.2 OVERACTIVE BLADDER

7.3 URINARY INCONTINENCE

7.4 CYSTITIS

7.5 INTERSTITIAL CYSTITIS

7.6 BLADDER CANCER

7.7 OTHERS

8 GLOBAL BLADDER DISORDERS MARKET, BY TREATMENT TYPE

8.1 OVERVIEW

8.2 MEDICATION

8.2.1 TOLTERODINE

8.2.2 MIRABEGRON

8.2.3 FESOTERODINE

8.2.4 OXYBUTYNIN

8.2.5 SOLIFENACIN

8.2.6 DARIFENACIN

8.2.7 TROSPIUM

8.2.8 OTHERS

8.3 SURGERY

8.3.1 SURGERY TO INCREASE BLADDER CAPACITY

8.3.2 BLADDER REMOVAL

8.3.3 OTHERS

8.4 OTHERS

9 GLOBAL BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL

9.1 OVERVIEW

9.2 DIRECT

9.3 RETAIL

10 GLOBAL BLADDER DISORDERS MARKET, BY END USER

10.1 OVERVIEW

10.2 HOSPITALS

10.3 CLINICS

10.4 AMBULATORY SURGICAL CENTERS

10.5 OTHERS

11 GLOBAL BLADDER DISORDERS MARKET, BY GEOGRAPHY

11.1 OVERVIEW

11.2 NORTH AMERICA

11.2.1 U.S.

11.2.2 CANADA

11.2.3 MEXICO

11.3 EUROPE

11.3.1 GERMANY

11.3.2 U.K.

11.3.3 FRANCE

11.3.4 ITALY

11.3.5 SPAIN

11.3.6 TURKEY

11.3.7 RUSSIA

11.3.8 NETHERLANDS

11.3.9 SWITZERLAND

11.3.10 BELGIUM

11.3.11 REST OF EUROPE

11.4 ASIA-PACIFIC

11.4.1 CHINA

11.4.2 JAPAN

11.4.3 INDIA

11.4.4 AUSTRALIA

11.4.5 SOUTH KOREA

11.4.6 THAILAND

11.4.7 SINGAPORE

11.4.8 INDONESIA

11.4.9 MALAYSIA

11.4.10 VIETNAM

11.4.11 PHILIPPINES

11.4.12 REST OF ASIA-PACIFIC

11.5 SOUTH AMERICA

11.5.1 BRAZIL

11.5.2 ARGENTINA

11.5.3 REST OF SOUTH AMERICA

11.6 MIDDLE EAST AND AFRICA

11.6.1 SAUDI ARABIA

11.6.2 SOUTH AFRICA

11.6.3 UAE

11.6.4 EGYPT

11.6.5 ISRAEL

11.6.6 REST OF MIDDLE EAST AND AFRICA

12 GLOBAL BLADDER DISORDERS MARKET: COMPANY LANDSCAPE

12.1 COMPANY SHARE ANALYSIS: GLOBAL

12.2 COMPANY SHARE ANALYSIS: NORTH AMERICA

12.3 COMPANY SHARE ANALYSIS: EUROPE

12.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC

13 SWOT ANALYSIS

14 COMPANY PROFILE

14.1 MERCK AND CO. INC. (2021)

14.1.1 COMPANY SNAPSHOT

14.1.2 REVENUE ANALYSIS

14.1.3 COMPANY SHARE ANALYSIS

14.1.4 PRODUCT PORTFOLIO

14.1.5 RECENT DEVELOPMENT

14.2 ASTELLAS PHARMA INC. (2021)

14.2.1 COMPANY SNAPSHOT

14.2.2 REVENUE ANALYSIS

14.2.3 COMPANY SHARE ANALYSIS

14.2.4 PRODUCT PORTFOLIO

14.2.5 RECENT DEVELOPMENTS

14.3 BRISTOL-MYERS SQUIBB COMPANY (2021)

14.3.1 COMPANY SNAPSHOT

14.3.2 REVENUE ANALYSIS

14.3.3 COMPANY SHARE ANALYSIS

14.3.4 PRODUCT PORTFOLIO

14.3.5 RECENT DEVELOPMENT

14.4 BOSTON SCIENTIFIC CORPORATION (2021)

14.4.1 COMPANY SNAPSHOT

14.4.2 REVENUE ANALYSIS

14.4.3 COMPANY SHARE ANALYSIS

14.4.4 PRODUCT PORTFOLIO

14.4.5 RECENT DEVELOPMENT

14.5 VIATRIS INC. (2021)

14.5.1 COMPANY SNAPSHOT

14.5.2 REVENUE ANALYSIS

14.5.3 COMPANY SHARE ANALYSIS

14.5.4 PRODUCT PORTFOLIO

14.5.5 RECENT DEVELOPMENT

14.6 ABBVIE (2021)

14.6.1 COMPANY SNAPSHOT

14.6.2 REVENUE ANALYSIS

14.6.3 PRODUCT PORTFOLIO

14.6.4 RECENT DEVELOPMENT

14.7 AXONICS, INC. (2021)

14.7.1 COMPANY SNAPSHOT

14.7.2 REVENUE ANALYSIS

14.7.3 PRODUCT PORTFOLIO

14.7.4 RECENT DEVELOPMENT

14.8 BLUE WIND MEDICAL (2021)

14.8.1 COMPANY SNAPSHOT

14.8.2 PRODUCT PORTFOLIO

14.8.3 RECENT DEVELOPMENT

14.9 COLOPLAST CORP. (2021)

14.9.1 COMPANY SNAPSHOT

14.9.2 REVENUE ANALYSIS

14.9.3 PRODUCT PORTFOLIO

14.1 GAYLORD CHEMICAL COMPANY, LLC (2021)

14.10.1 COMPANY SNAPSHOT

14.10.2 PRODUCT PORTFOLIO

14.10.3 RECENT DEVELOPMENT

14.11 JOHNSON & JOHNSON SERVICES, INC. (2021)

14.11.1 COMPANY SNAPSHOT

14.11.2 REVENUE ANALYSIS

14.11.3 PRODUCT PORTFOLIO

14.11.4 RECENT DEVELOPMENT

14.12 KYORIN PHARMACEUTICAL CO., LTD. (A SUBSIDIARY OF KYORIN HOLDINGS, INC.) (2021)

14.12.1 COMPANY SNAPSHOT

14.12.2 PRODUCT PORTFOLIO

14.12.3 RECENT DEVELOPMENTS

14.13 LABORIE (2021)

14.13.1 COMPANY SNAPSHOT

14.13.2 PRODUCT PORTFOLIO

14.13.3 RECENT DEVELOPMENT

14.14 MEDTRONIC (2021)

14.14.1 COMPANY SNAPSHOT

14.14.2 REVENUE ANALYSIS

14.14.3 PRODUCT PORTFOLIO

14.14.4 RECENT DEVELOPMENTS

14.15 PFIZER INC. (2021)

14.15.1 COMPANY SNAPSHOT

14.15.2 REVENUE ANALYSIS

14.15.3 PRODUCT PORTFOLIO

14.15.4 RECENT DEVELOPMENTS

14.16 VALENCIA TECHNOLOGIES (2021)

14.16.1 COMPANY SNAPSHOT

14.16.2 PRODUCT PORTFOLIO

14.16.3 RECENT DEVELOPMENT

14.17 SUN PHAMACEUTICAL INDUSTRIES LTD. (2021)

14.17.1 COMPANY SNAPSHOT

14.17.2 REVENUE ANALYSIS

14.17.3 PRODUCT PORTFOLIO

14.17.4 RECENT DEVELOPMENT

14.18 SWATI SPENTOSE (2021)

14.18.1 COMPANY SNAPSHOT

14.18.2 PRODUCT PORTFOLIO

14.18.3 RECENT DEVELOPMENT

14.19 UROVANT SCIENCES (2021)

14.19.1 COMPANY SNAPSHOT

14.19.2 PRODUCT PORTFOLIO

14.19.3 RECENT DEVELOPMENT

14.2 ZYDUS GROUP (2021)

14.20.1 COMPANY SNAPSHOT

14.20.2 PRODUCT PORTFOLIO

14.20.3 RECENT DEVELOPMENT

15 QUESTIONNAIRE

16 RELATED REPORTS

Lista de Tablas

TABLE 1 GLOBAL BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 2 GLOBAL OVERACTIVE BLADDER IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 3 GLOBAL URINARY INCONTINENCE IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 4 GLOBAL CYSTITIS IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 5 GLOBAL INTERSTITIAL CYSTITIS IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 6 GLOBAL BLADDER CANCER IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 7 GLOBAL OTHERS IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 8 GLOBAL BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 9 GLOBAL MEDICATION IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 10 GLOBAL MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 11 GLOBAL SURGERY IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 12 GLOBAL SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 13 GLOBAL OTHERS IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 14 GLOBAL BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 15 GLOBAL DIRECT IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 16 GLOBAL RETAIL IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 17 GLOBAL BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 18 GLOBAL HOSPITALS IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 19 GLOBAL CLINICS IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 20 GLOBAL AMBULATORY SURGICAL CENTERS IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 21 GLOBAL OTHERS IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 22 GLOBAL BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 23 NORTH AMERICA BLADDER DISORDERS MARKET, BY COUNTRY, 2020-2029 (USD MILLION)

TABLE 24 NORTH AMERICA BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 25 NORTH AMERICA BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 26 NORTH AMERICA MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 27 NORTH AMERICA SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 28 NORTH AMERICA BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 29 NORTH AMERICA BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 30 U.S. BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 31 U.S. BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 32 U.S. MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 33 U.S. SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 34 U.S. BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 35 U.S. BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 36 CANADA BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 37 CANADA BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 38 CANADA MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 39 CANADA SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 40 CANADA BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 41 CANADA BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 42 MEXICO BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 43 MEXICO BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 44 MEXICO MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 45 MEXICO SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 46 MEXICO BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 47 MEXICO BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 48 EUROPE BLADDER DISORDERS MARKET, BY COUNTRY, 2020-2029 (USD MILLION)

TABLE 49 EUROPE BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 50 EUROPE BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 51 EUROPE MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 52 EUROPE SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 53 EUROPE BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 54 EUROPE BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 55 GERMANY BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 56 GERMANY BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 57 GERMANY MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 58 GERMANY SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 59 GERMANY BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 60 GERMANY BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 61 U.K. BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 62 U.K. BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 63 U.K. MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 64 U.K. SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 65 U.K. BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 66 U.K. BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 67 FRANCE BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 68 FRANCE BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 69 FRANCE MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 70 FRANCE SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 71 FRANCE BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 72 FRANCE BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 73 ITALY BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 74 ITALY BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 75 ITALY MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 76 ITALY SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 77 ITALY BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 78 ITALY BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 79 SPAIN BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 80 SPAIN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 81 SPAIN MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 82 SPAIN. SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 83 SPAIN BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 84 SPAIN BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 85 TURKEY BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 86 TURKEY BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 87 TURKEY MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 88 TURKEY SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 89 TURKEY BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 90 TURKEY BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 91 RUSSIA BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 92 RUSSIA BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 93 RUSSIA MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 94 RUSSIA SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 95 RUSSIA BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 96 RUSSIA BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 97 NETHERLANDS BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 98 NETHERLANDS BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 99 NETHERLANDS MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 100 NETHERLANDS SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 101 NETHERLANDS BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 102 NETHERLANDS BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 103 SWITZERLAND BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 104 SWITZERLAND BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 105 SWITZERLAND MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 106 SWITZERLAND SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 107 SWITZERLAND BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 108 SWITZERLAND BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 109 BELGIUM BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 110 BELGIUM BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 111 BELGIUM MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 112 BELGIUM SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 113 BELGIUM BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 114 BELGIUM BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 115 REST OF EUROPE BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 116 ASIA-PACIFIC BLADDER DISORDERS MARKET, BY COUNTRY, 2020-2029 (USD MILLION)

TABLE 117 ASIA-PACIFIC BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 118 ASIA-PACIFIC BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 119 ASIA-PACIFIC MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 120 ASIA-PACIFIC SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 121 ASIA-PACIFIC BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 122 ASIA-PACIFIC BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 123 CHINA BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 124 CHINA BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 125 CHINA MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 126 CHINA SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 127 CHINA BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 128 CHINA BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 129 JAPAN BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 130 JAPAN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 131 JAPAN MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 132 JAPAN SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 133 JAPAN BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 134 JAPAN BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 135 INDIA BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 136 INDIA BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 137 INDIA MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 138 INDIA SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 139 INDIA BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 140 INDIA BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 141 AUSTRALIA BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 142 AUSTRALIA BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 143 AUSTRALIA MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 144 AUSTRALIA SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 145 AUSTRALIA BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 146 AUSTRALIA BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 147 SOUTH KOREA BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 148 SOUTH KOREA BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 149 SOUTH KOREA MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 150 SOUTH KOREA SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 151 SOUTH KOREA BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 152 SOUTH KOREA BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 153 THAILAND BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 154 THAILAND BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 155 THAILAND MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 156 THAILAND SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 157 THAILAND BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 158 THAILAND BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 159 SINGAPORE BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 160 SINGAPORE BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 161 SINGAPORE MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 162 SINGAPORE SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 163 SINGAPORE BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 164 SINGAPORE BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 165 INDONESIA BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 166 INDONESIA BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 167 INDONESIA MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 168 INDONESIA. SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 169 INDONESIA BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 170 INDONESIA BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 171 MALAYSIA BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 172 MALAYSIA BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 173 MALAYSIA MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 174 MALAYSIA SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 175 MALAYSIA BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 176 MALAYSIA BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 177 VIETNAM BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 178 VIETNAM BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 179 VIETNAM MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 180 VIETNAM SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 181 VIETNAM BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 182 VIETNAM BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 183 PHILIPPINES BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 184 PHILIPPINES BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 185 PHILIPPINES MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 186 PHILIPPINES SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 187 PHILIPPINES BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 188 PHILIPPINES BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 189 REST OF ASIA-PACIFIC BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 190 SOUTH AMERICA BLADDER DISORDERS MARKET, BY COUNTRY, 2020-2029 (USD MILLION)

TABLE 191 SOUTH AMERICA BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 192 SOUTH AMERICA BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 193 SOUTH AMERICA MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 194 SOUTH AMERICA SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 195 SOUTH AMERICA BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 196 SOUTH AMERICA BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 197 BRAZIL BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 198 BRAZIL BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 199 BRAZIL MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 200 BRAZIL SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 201 BRAZIL BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 202 BRAZIL BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 203 ARGENTINA BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 204 ARGENTINA BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 205 ARGENTINA MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 206 ARGENTINA SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 207 ARGENTINA BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 208 ARGENTINA BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 209 REST OF SOUTH AMERICA BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 210 MIDDLE EAST AND AFRICA BLADDER DISORDERS MARKET, BY COUNTRY, 2020-2029 (USD MILLION)

TABLE 211 MIDDLE EAST AND AFRICA BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 212 MIDDLE EAST AND AFRICA BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 213 MIDDLE EAST AND AFRICA MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 214 MIDDLE EAST AND AFRICA SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 215 MIDDLE EAST AND AFRICA BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 216 MIDDLE EAST AND AFRICA BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 217 SAUDI ARABIA BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 218 SAUDI ARABIA BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 219 SAUDI ARABIA MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 220 SAUDI ARABIA SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 221 SAUDI ARABIA BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 222 SAUDI ARABIA BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 223 SOUTH AFRICA BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 224 SOUTH AFRICA BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 225 SOUTH AFRICA MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 226 SOUTH AFRICA SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 227 SOUTH AFRICA BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 228 SOUTH AFRICA BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 229 UAE BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 230 UAE BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 231 UAE MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 232 UAE SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 233 UAE BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 234 UAE BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 235 EGYPT BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 236 EGYPT BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 237 EGYPT MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 238 EGYPT SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 239 EGYPT BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 240 EGYPT BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 241 ISRAEL BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 242 ISRAEL BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 243 ISRAEL MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 244 ISRAEL SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 245 ISRAEL BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 246 ISRAEL BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 247 REST OF MIDDLE EAST AND AFRICA BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)

Lista de figuras

FIGURE 1 GLOBAL BLADDER DISORDERS MARKET: SEGMENTATION

FIGURE 2 GLOBAL BLADDER DISORDERS MARKET: DATA TRIANGULATION

FIGURE 3 GLOBAL BLADDER DISORDERS MARKET: DROC ANALYSIS

FIGURE 4 GLOBAL BLADDER DISORDERS MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS

FIGURE 5 GLOBAL BLADDER DISORDERS MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 GLOBAL BLADDER DISORDERS MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 GLOBAL BLADDER DISORDERS MARKET: DBMR MARKET POSITION GRID

FIGURE 8 GLOBAL BLADDER DISORDERS MARKET: MARKET END USER COVERAGE GRID

FIGURE 9 GLOBAL BLADDER DISORDERS MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 GLOBAL BLADDER DISORDERS MARKET: SEGMENTATION

FIGURE 11 RISING EPIDEMIC AND PANDEMIC OUTBREAK AND INCREASING PREVALENCE OF BLADDER DISORDERS EXPECTED TO DRIVE THE GLOBAL BLADDER DISORDERS MARKET IN THE FORECAST PERIOD OF 2022 TO 2029

FIGURE 12 OVERACTIVE BLADDER SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL BLADDER DISORDERS MARKET IN 2022 & 2029

FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL BLADDER DISORDERS MARKET AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2022 TO 2029

FIGURE 14 ASIA-PACIFIC IS THE FASTEST GROWING MARKET FOR BLADDER DISORDERS MANUFACTURERS IN THE FORECAST PERIOD OF 2022 TO 2029

FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE GLOBAL BLADDER DISORDER MARKET

FIGURE 16 GLOBAL BLADDER DISORDERS MARKET: BY TYPE, 2021

FIGURE 17 GLOBAL BLADDER DISORDERS MARKET: BY TYPE, 2022-2029 (USD MILLION)

FIGURE 18 GLOBAL BLADDER DISORDERS MARKET: BY TYPE, CAGR (2022-2029)

FIGURE 19 GLOBAL BLADDER DISORDERS MARKET: BY TYPE, LIFELINE CURVE

FIGURE 20 GLOBAL BLADDER DISORDERS MARKET: BY TREATMENT TYPE, 2021

FIGURE 21 GLOBAL BLADDER DISORDERS MARKET: BY TREATMENT TYPE, 2022-2029 (USD MILLION)

FIGURE 22 GLOBAL BLADDER DISORDERS MARKET: BY TREATMENT TYPE, CAGR (2022-2029)

FIGURE 23 GLOBAL BLADDER DISORDERS MARKET: BY TREATMENT TYPE, LIFELINE CURVE

FIGURE 24 GLOBAL BLADDER DISORDERS MARKET: BY DISTRIBUTION CHANNEL, 2021

FIGURE 25 GLOBAL BLADDER DISORDERS MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION)

FIGURE 26 GLOBAL BLADDER DISORDERS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)

FIGURE 27 GLOBAL BLADDER DISORDERS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 28 GLOBAL BLADDER DISORDERS MARKET: BY END USER, 2021

FIGURE 29 GLOBAL BLADDER DISORDERS MARKET: BY END USER, 2022-2029 (USD MILLION)

FIGURE 30 GLOBAL BLADDER DISORDERS MARKET: BY END USER, CAGR (2022-2029)

FIGURE 31 GLOBAL BLADDER DISORDERS MARKET: BY END USER, LIFELINE CURVE

FIGURE 32 GLOBAL BLADDER DISORDERS MARKET: SNAPSHOT (2021)

FIGURE 33 GLOBAL BLADDER DISORDERS MARKET: BY REGION (2021)

FIGURE 34 GLOBAL BLADDER DISORDERS MARKET: BY REGION (2022 & 2029)

FIGURE 35 GLOBAL BLADDER DISORDERS MARKET: BY REGION (2021 & 2029)

FIGURE 36 GLOBAL BLADDER DISORDERS MARKET: BY TYPE (2022-2029)

FIGURE 37 NORTH AMERICA BLADDER DISORDERS MARKET: SNAPSHOT (2021)

FIGURE 38 NORTH AMERICA BLADDER DISORDERS MARKET: BY COUNTRY (2021)

FIGURE 39 NORTH AMERICA BLADDER DISORDERS MARKET: BY COUNTRY (2022 & 2029)

FIGURE 40 NORTH AMERICA BLADDER DISORDERS MARKET: BY COUNTRY (2021 & 2029)

FIGURE 41 NORTH AMERICA BLADDER DISORDERS MARKET: BY TYPE (2022-2029)

FIGURE 42 EUROPE BLADDER DISORDERS MARKET: SNAPSHOT (2021)

FIGURE 43 EUROPE BLADDER DISORDERS MARKET: BY COUNTRY (2021)

FIGURE 44 EUROPE BLADDER DISORDERS MARKET: BY COUNTRY (2022 & 2029)

FIGURE 45 EUROPE BLADDER DISORDERS MARKET: BY COUNTRY (2021 & 2029)

FIGURE 46 EUROPE BLADDER DISORDERS MARKET: BY TYPE (2022-2029)

FIGURE 47 ASIA-PACIFIC BLADDER DISORDERS MARKET: SNAPSHOT (2021)

FIGURE 48 ASIA-PACIFIC BLADDER DISORDERS MARKET: BY COUNTRY (2021)

FIGURE 49 ASIA-PACIFIC BLADDER DISORDERS MARKET: BY COUNTRY (2022 & 2029)

FIGURE 50 ASIA-PACIFIC BLADDER DISORDERS MARKET: BY COUNTRY (2021 & 2029)

FIGURE 51 ASIA-PACIFIC BLADDER DISORDERS MARKET: BY TYPE (2022-2029)

FIGURE 52 SOUTH AMERICA BLADDER DISORDERS MARKET: SNAPSHOT (2021)

FIGURE 53 SOUTH AMERICA BLADDER DISORDERS MARKET: BY COUNTRY (2021)

FIGURE 54 SOUTH AMERICA BLADDER DISORDERS MARKET: BY COUNTRY (2022 & 2029)

FIGURE 55 SOUTH AMERICA BLADDER DISORDERS MARKET: BY COUNTRY (2021 & 2029)

FIGURE 56 SOUTH AMERICA BLADDER DISORDERS MARKET: BY TYPE (2022-2029)

FIGURE 57 MIDDLE EAST AND AFRICA BLADDER DISORDERS MARKET: SNAPSHOT (2021)

FIGURE 58 MIDDLE EAST AND AFRICA BLADDER DISORDERS MARKET: BY COUNTRY (2021)

FIGURE 59 MIDDLE EAST AND AFRICA BLADDER DISORDERS MARKET: BY COUNTRY (2022 & 2029)

FIGURE 60 MIDDLE EAST AND AFRICA BLADDER DISORDERS MARKET: BY COUNTRY (2021 & 2029)

FIGURE 61 MIDDLE EAST AND AFRICA BLADDER DISORDERS MARKET: BY TYPE (2022-2029)

FIGURE 62 GLOBAL BLADDER DISORDERS MARKET: COMPANY SHARE 2021 (%)

FIGURE 63 NORTH AMERICA BLADDER DISORDERS MARKET: COMPANY SHARE 2021 (%)

FIGURE 64 EUROPE BLADDER DISORDERS MARKET: COMPANY SHARE 2021 (%)

FIGURE 65 ASIA-PACIFIC BLADDER DISORDERS MARKET: COMPANY SHARE 2021 (%)

Ver información detallada Right Arrow

Metodología de investigación

La recopilación de datos y el análisis del año base se realizan utilizando módulos de recopilación de datos con muestras de gran tamaño. La etapa incluye la obtención de información de mercado o datos relacionados a través de varias fuentes y estrategias. Incluye el examen y la planificación de todos los datos adquiridos del pasado con antelación. Asimismo, abarca el examen de las inconsistencias de información observadas en diferentes fuentes de información. Los datos de mercado se analizan y estiman utilizando modelos estadísticos y coherentes de mercado. Además, el análisis de la participación de mercado y el análisis de tendencias clave son los principales factores de éxito en el informe de mercado. Para obtener más información, solicite una llamada de un analista o envíe su consulta.

La metodología de investigación clave utilizada por el equipo de investigación de DBMR es la triangulación de datos, que implica la extracción de datos, el análisis del impacto de las variables de datos en el mercado y la validación primaria (experto en la industria). Los modelos de datos incluyen cuadrícula de posicionamiento de proveedores, análisis de línea de tiempo de mercado, descripción general y guía del mercado, cuadrícula de posicionamiento de la empresa, análisis de patentes, análisis de precios, análisis de participación de mercado de la empresa, estándares de medición, análisis global versus regional y de participación de proveedores. Para obtener más información sobre la metodología de investigación, envíe una consulta para hablar con nuestros expertos de la industria.

Personalización disponible

Data Bridge Market Research es líder en investigación formativa avanzada. Nos enorgullecemos de brindar servicios a nuestros clientes existentes y nuevos con datos y análisis que coinciden y se adaptan a sus objetivos. El informe se puede personalizar para incluir análisis de tendencias de precios de marcas objetivo, comprensión del mercado de países adicionales (solicite la lista de países), datos de resultados de ensayos clínicos, revisión de literatura, análisis de mercado renovado y base de productos. El análisis de mercado de competidores objetivo se puede analizar desde análisis basados ​​en tecnología hasta estrategias de cartera de mercado. Podemos agregar tantos competidores sobre los que necesite datos en el formato y estilo de datos que esté buscando. Nuestro equipo de analistas también puede proporcionarle datos en archivos de Excel sin procesar, tablas dinámicas (libro de datos) o puede ayudarlo a crear presentaciones a partir de los conjuntos de datos disponibles en el informe.

Preguntas frecuentes

The market value is expected USD 22,342.48 million by 2029.
The market is to grow at a CAGR of 11.4% during the forecast by 2029.
The major players operating in the Bladder Disorders Market are Medtronic, Laborie, Boston Scientific Corporation, Pfizer Inc., Astellas Pharma Inc., KYORIN Pharmaceutical Co., Ltd. (A subsidiary of KYORIN Holdings, Inc.), Bristol-Myers Squibb Company, Johnson & Johnson Services, Inc., Axonics, Inc., Merck & Co., Inc., Viatris Inc., Blue Wind Medical, Valencia Technologies, Gaylord Chemical Company, L.L.C., Coloplast Corp, AbbVie Inc., Sun Pharmaceutical Industries Ltd., Zydus Group, Swati Spentose, Urovant Sciences among others.
The major countries covered in the Bladder Disorders Market are U.S., Canada, Mexico, Germany, U.K., France, Italy, Spain, Turkey, Russia, Netherlands, Switzerland, Blegium and Rest of Europe, China, Japan, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Brazil, Argentina, Peru, Rest of South America, South Africa, Saudi Arabia, U.A.E, Egypt, Israel, Rest of the Middle East and Africa.